It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
VHHs are single domain antibodies derived from heavy chain antibodies found in camelid species. VHHs are attractive therapeutics as they are easy to produce, are stable, and can bind targets inaccessible to traditional antibody formats. However, one potential disadvantage associated with VHHs is rapid renal clearance resulting in a short serum half-life. One innovative solution to increase the serum half-life of VHH is to make use of multivalent VHH. In this format, a therapeutic VHH is genetically fused to a second VHH specific for the abundant plasma protein, serum albumin. Such multi-specific VHH targeting serum albumin increase the half-life of therapeutic VHHs. The use of a VHH that cross react with research animal albumin is particularly desirable, as the bispecific VHH could be used in pre-clinical animal trials. Previously, a panel of VHHs which cross-react with serum albumins from human, macaques, mouse, and rat were generated. To determine the basis of VHH cross-species specificity, the structure of VHH M79 in complex with human serum albumin (HSA) was obtained through X-ray crystallography. The structure revealed that only two of three CDR loops (CDR2 and CDR3) formed polar contacts with HSA. M79 bound to the apex of HSA domain II, specifically forming polar contacts with residues Asp308, Asp314, Asn318, and Glu321 on HSA. Comparison of serum albumin sequences from human, macaques, mouse, and rat show that the interacting residues are highly conserved across the four species. Molecular docking of M79 with serum albumin from macaques, rats, and mice shows that the VHH also binds to domain II of these proteins. Finally, competitive binding experiments revealed that two other VHHs (R11 and R28) compete with M79, suggesting they also bind albumin domain II. This work gives insights into the cross-species specificity of M79, R11, and R28 towards serum albumin and can bolster the use of the VHHs in animal model experiments.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer